Proteomics-Driven Cancer Biomarkers for Early Detection and Targeted Therapy: Insights from the Middle East

Proteomics has become a transformative tool in oncology, offering unique opportunities for early detection, diagnosis, and cancer stratification. By enabling large-scale analysis of protein expression, interactions, and post-translational modifications, proteomics facilitates the discovery of clinically relevant biomarkers that reflect the dynamic molecular state of disease. These biomarkers, often detectable in easily accessible body fluids like blood, urine, or saliva, serve as minimally invasive "liquid biopsies" capable of identifying malignancies at asymptomatic stages. The integration of high-resolution mass spectrometry with advanced computational methods, including machine learning and network-based analytics, has accelerated the identification of reliable biomarker panels for cancer prediction, monitoring, and treatment response. Proteomics not only complements genomic and transcriptomic data but also provides a functional view of cellular states, bridging the gap between genotype and phenotype. This is especially important for customizing personalized treatment plans based on tumor-specific protein profiles, thus reducing the off-target effects of traditional therapies. Furthermore, proteomics plays a crucial role in finding cancer-related mechanisms, such as immune evasion, angiogenesis, and metastatic progression. Although proteomics-based biomarker discovery holds critical promise for cancer diagnosis and precision medicine, substantial translational challenges remain. These include assay standardization, sample accessibility from a regional biobank, regulatory obstacles, cross-population validation, and the integration of discoveries into clinical workflows. In this perspective, we offer a comprehensive overview of the latest progress in proteomics-driven cancer biomarker discovery, with a particular focus on its translational potential in early detection and precision oncology. The increasing incidence of cancer in the Middle East is highlighted, necessitating an urgent expansion of research into population-specific biomarkers.